Tamoxifen

Risk of Endometrial Abnormalities With Adjuvant Tamoxifen for Early Stage Breast Cancer Is Low

Risk of Endometrial Abnormalities With Adjuvant Tamoxifen for Early Stage Breast Cancer Is Low

By

For women receiving tamoxifen in the adjuvant setting for early stage breast cancer or as a preventive for high risk of breast cancer, the risk of developing endometrial pathology in those with negative uterine examination findings prior to treatment is very low.

Adding Two Inhibitors Enhances Effectiveness of Tamoxifen in ER-positive Breast Cancer

By

Combining 2 existing chemotherapy drugs, a DNMT1 inhibitor and a histone deacetylase inhibitor, reduced the numbers of cancer stem cells and improved survival in a mouse model.

Targeting Long noncoding RNAs in Breast Cancer May Prevent Tamoxifen Resistance

Targeting Long noncoding RNAs in Breast Cancer May Prevent Tamoxifen Resistance

By

New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials

[OncoTargets and Therapy] This article examines possible survival benefits of ovarian function suppression (OFS) when combined with adjuvant tamoxifen treatment for breast cancer in premenopausal women.

Survival mechanism in breast cancer cells is found to result in poorer outcomes for African American women

By

The worse outcomes for African American women with estrogen-receptor positive (ER+) breast cancer, when compared with European American patients, appears to be related to a reduced cellular sensitivity to tamoxifen.

Benefit of breast cancer prevention drug varies among at-risk women

By

Researchers examined the benefits and risks associated with taking drug tamoxifen for breast cancer prevention.

Adding ovarian suppression to tamoxifen reduced recurrence for some premenopausal breast cancer

By

Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.

Tamoxifen found to lower breast cancer rates among high-risk women in trial

By

The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.

Preventative therapies for healthy women at high risk of breast cancer

Preventative therapies for healthy women at high risk of breast cancer

SERMs and aromatase inhibitors have been proven to be excellent agents in the preventive setting for ER-positive breast cancer, but newer agents must be found specifically for ER-negative breast cancers, which mostly occur in premenopausal women.

Gel formulation of tamoxifen significantly reduces side effects related to the oral formulation

By

A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects.

Sleeping in darkness boosts breast cancer drug effectiveness

Sleeping in darkness boosts breast cancer drug effectiveness

Keeping a light on at night can suppress the body's production of a hormone called melatonin, possibly reducing the effectiveness of the breast-cancer drug tamoxifen, a study suggests.

Exposure to dim light at night may lead to tamoxifen resistance in breast cancer

By

For rats bearing human breast tumors, exposure to dim light at night made the tumors resistant to the breast cancer drug tamoxifen, according to recently published data.

Gene marker may help predict breast cancer response to tamoxifen

Gene marker may help predict breast cancer response to tamoxifen

Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy.

Skin gel helps fight against breast cancer

Skin gel helps fight against breast cancer

A gel containing the drug tamoxifen and applied to the skin was as effective as the pill form in reducing the growth of breast cancer cells in women with noninvasive cancer.

Drug resistance reversed when tamoxifen is paired with antimalarial agent

By

The antimalarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen in mice, according to investigators.

ASCO: Exemestane more effective than tamoxifen for early breast cancer

ASCO: Exemestane more effective than tamoxifen for early breast cancer

For premenopausal women with hormone receptor-positive early breast cancer, exemestane plus ovarian function suppression (OFS) is superior to tamoxifen plus OFS.

Adjuvant endocrine therapy and alopecia

Adjuvant endocrine therapy and alopecia

By

A patient on adjuvant endocrine therapy for breast cancer is complaining of hair loss. Could the alopecia be due to her endocrine therapy?

Paroxetine and chemoprevention drugs

Paroxetine and chemoprevention drugs

By

Can the drug paroxetine mesylate (Brisdelle, Paxil) be given to patients taking a chemoprevention drug such as raloxifene (Evista) or any of the aromatase inhibitors?

Existing treatment may stop tamoxifen-induced fog

Existing treatment may stop tamoxifen-induced fog

Researchers have not only confirmed that tamoxifen induces cognitive dysfunction in users, they have also found an existing treatment that can prevent this adverse effect.

CNS cell death a result of tamoxifen exposure

MEK1/2 inhibition rescues glial progenitor cells from toxicity; prevents tamoxifen-induced cell death.

Estrogen enhancers tied to aggressive breast cancer

Estrogen enhancers tied to aggressive breast cancer

By

Adding to the picture of what prompts breast cancer to form, researchers have found that distant estrogen response elements can act independently of oncogenes to spur tumor development.

Tamoxifen halves breast cancer risk in high-risk women

By

A global study of women with inherited mutations in BRCA1 or BRCA2 found that tamoxifen could halve the risk for breast cancer in the contralateral (opposite-side) breast in these high-risk women.

Breast cancer prophylaxis updated

Breast cancer prophylaxis updated

Clinicians should discuss the prophylactic use of tamoxifen as well as two other agents with women 35 years and older and at increased risk of ER-positive breast cancer, per ASCO recommendations.

BH3 mimetics improved tamoxifen therapy in breast cancer

By

The addition of BH3 mimetics to standard tamoxifen treatment improved the effectiveness of hormone therapy in luminal B cancers, an aggressive subtype of ER-positive breast cancer.

Biomarker shows when letrozole may stop breast cancer recurrence

By

A biomarker reflecting expression levels of two genes in tumor tissue has been found to predict which patients may be at risk for late recurrence of estrogen receptor (ER)-positive breast cancer, and when adjuvant letrozole therapy may be of benefit.

Biomarkers may predict who will respond to breast cancer prevention therapy

By

Single nucleotide polymorphisms (SNPs) in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene.

USPSTF study: Risk-reducing meds may be OK for women at high risk for breast cancer

Women at high risk for breast cancer may benefit most from preventive drug therapy, shows a study done for the US Preventive Services Task Force.

USPSTF recommends tamoxifen, raloxifene for women at risk of breast cancer

USPSTF recommends tamoxifen, raloxifene for women at risk of breast cancer

The U.S. Preventive Services Task Force recommends that women who are at increased risk of primary breast cancer consider taking preventive medications such as tamoxifen.

Genotype testing not warranted

Genotype testing not warranted

By

Is CYP2D6 genotyping for tamoxifen (Nolvadex) sensitivity before use of the drug beneficial?

Extending tamoxifen reduced risk for late breast cancer recurrence and improved survival

By

Ten years of adjuvant treatment with tamoxifen provided women with ER-positive breast cancer greater protection against late recurrence and death from breast cancer compared with the current standard of 5 years of tamoxifen.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs